Ocala Cardiovascular Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$165,187	6
2024	Research	$183,138	2
2023	Research	$21,259	1
2022	Research	$1,100	1
2021	Research	$275	1
2020	Research	$9,462	3

Breakdown

Who paid Research payments · program years 2020–2025

Amgen Inc. $342,083 11 payments
Novartis Pharmaceuticals Corporation $38,339 3 payments

Studies the money was for Research payments · program years 2020–2025

OCEANa-Outcomes P3 CV $183,138 2 payments
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) $69,482 1 payment
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) $47,967 1 payment
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C $26,700 1 payment
Phase 3 - Cardiovascular Outcomes Trial $21,259 1 payment
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) $11,639 2 payments
Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) $9,737 4 payments
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) $9,399 1 payment
P0 ASCVD Olpasiran Prescreening for CVOT $1,100 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.